PHARMAC has decided to list a range of haemophilia treatments in Section B of the Pharmaceutical Schedule.
PHARMAC has approved a proposal relating to a provisional agreement with Actavis New Zealand Ltd for the oral contraceptives ethinyloestradiol 20 mcg with levonorgestrel 100 mcg and ethinyloestradiol 30 mcg with levonorgestrel 150 mcg.
PHARMAC is seeking feedback on a provisional agreement with Abbott Laboratories (NZ) Limited to fully subsidise its brand of ferrous sulphate in Section B and list ferrous sulphate in Part II of Section H of the Pharmaceutical Schedule.
PHARMAC is pleased to announce the approval of an agreement with Merck Sharp and Dohme (New Zealand) Ltd relating to the supply of montelukast (Singulair) for the treatment of pre-school wheeze, exercise-induced asthma and aspirin desensitisation from 1 December 2013.
PHARMAC has decided to widen access to levonorgestrel intra-uterine system, 20 mcg per day (levonorgestrel IUS) in DHB hospitals.
PHARMAC invites tenders for the supply of certain pharmaceuticals to DHB hospitals and/or to community pharmacies in New Zealand. An updated Invitation to Tender is now available. Closed.
The 2013/14 Invitation to Tender (2013/14 ITT) has been distributed today via the electronic tender (eTender) system.
PHARMAC has issued an updated and clarified 2013/14 Invitation to Tender.
PHARMAC is seeking public feedback on changes to the national immunisation schedule - including the addition of vaccines for rotavirus and varicella.
PHARMAC is seeking feedback on a proposal to amend the Pharmaceutical Schedule rules relating to the Dispensing Frequency rule. This would result in increased frequency of subsidised dispensing for some patients in residential care. PHARMAC is also proposing to add zopiclone to the Safety Medicines list. Closes: Friday, 6 December 2013.
PHARMAC is seeking feedback on proposals relating to provisional agreements with a number of suppliers for the supply of vaccines for the New Zealand National Immunisation Schedule. Closed: Wednesday, 20 November 2013.
PHARMAC is seeking feedback on a proposal relating to a provisional agreement with GlaxoSmithKline for a number of products.
Following a notification of discontinuation by Dr Reddys of their brand of pramipexole, PHARMAC has entered into an agreement with Deva Holdings NZ Limited for the temporary listing of their brand of pramipexole, Ramipex, on the Pharmaceutical Schedule from 1 December 2013.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.
PHARMAC is seeking feedback on a proposal to reduce the price and subsidies for erlotinib (Tarceva) while making it more widely available. Closed: 5 pm, Friday, 8 November 2013.
Proposal for sole supply of imatinib for indications other than Gastro Intestinal Stromal Tumours (GIST)
PHARMAC is seeking feedback on a proposal relating to the funding of and access to imatinib. Closes: 12 November 2013.
PHARMAC is seeking further input from the public as it decides how to apply its existing approach to managing hospital medical devices.
PHARMAC has secured the national supply of influenza vaccines for the next three years.
PHARMAC is seeking to understand further how it will need to further adapt PHARMAC operating policies and procedures to be suitable for managing hospital medical devices. Closed: 5 pm, 29 November 2013.
PHARMAC invites proposals for the supply of nicotine replacement therapy (including, but not limited to, nicotine gum, lozenges and patches) in New Zealand. Extended response period: closed.